Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain

International Journal of Oncology

Volumn 47, Issue 2, 2015, Pages 601-609

  Liu, Hao ^a   Seijsing, Johan ^a   Frejd, Fredrik Y ^b,c   Tolmachev, Vladimir ^c   Gräslund, Torbjörn ^a  

^a ALBANOVA UNIVERSITY CENTER   (Sweden)

^b Affibody AB   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Affibody molecule; Albumin binding domain; HER2; Immunotoxin; PE38

Indexed keywords

ABD PE 38X8; ALBUMIN BINDING DOMAIN; ANTINEOPLASTIC AGENT; BOVINE SERUM ALBUMIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HUMAN SERUM ALBUMIN; PROTEIN; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A; SERUM ALBUMIN; UNCLASSIFIED DRUG; ALBUMINOID; BACTERIAL TOXIN; ERBB2 PROTEIN, HUMAN; EXOTOXIN; HYBRID PROTEIN; IMMUNOTOXIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TOXA PROTEIN, PSEUDOMONAS AERUGINOSA; VIRULENCE FACTOR;

A549 CELL LINE; AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; BIOSENSOR; CELL DENSITY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; HALF LIFE TIME; HUMAN; HUMAN CELL; IMMUNOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PSEUDOMONAS AERUGINOSA; WILD TYPE; ANIMAL; BOVINE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; GENETIC PROCEDURES; GENETICS; METABOLISM; MOUSE; NEOPLASMS; TUMOR CELL LINE;

ADP RIBOSE TRANSFERASES; ALBUMINS; ANIMALS; BACTERIAL TOXINS; BIOSENSING TECHNIQUES; CATTLE; CELL LINE, TUMOR; CELL SURVIVAL; EXOTOXINS; HALF-LIFE; HUMANS; IMMUNOTOXINS; MICE; NEOPLASMS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; VIRULENCE FACTORS;

EID: 84932646862     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3027     Document Type: Article

References (32)

1. Kreitman RJ: Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs 23: 1-13, 2009.
2. Alewine C, Hassan R and Pastan I: Advances in anticancer immunotoxin therapy. Oncologist 20: 176-185, 2015.
3. Martin-Killias P, Stefan N, Rothschild S, Plückthun A, Zangemeister-Wittke U and Zangemeister-Wittke U: A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity. Clin Cancer Res 17: 100-110, 2011.
4. Zielinski R, Lyakhov I, Jacobs A, Chertov O, Kramer-Marek G, Francella N, Stephen A, Fisher R, Blumenthal R and Capala J: Affitoxin-a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors. J Immunother 32: 817-825, 2009.
5. Zielinski R, Lyakhov I, Hassan M, Kuban M, Shafer-Weaver K, Gandjbakhche A and Capala J: HER2-affitoxin: A potent therapeutic agent for the treatment of HER2-overexpressing tumors. Clin Cancer Res 17: 5071-5081, 2011.
6. Mazor R, Vassall AN, Eberle JA, Beers R, Weldon JE, Venzon DJ, Tsang KY, Benhar I and Pastan I: Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A. Proc Natl Acad Sci USA 109: E3597-E3603, 2012.
7. Onda M, Beers R, Xiang L, Nagata S, Wang Q-C and Pastan I: An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci USA 105: 11311-11316, 2008.
8. Liu W, Onda M, Lee B, Kreitman RJ, Hassan R, Xiang L and Pastan I: Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc Natl Acad Sci USA 109: 11782-11787, 2012.
9. Onda M, Beers R, Xiang L, Lee B, Weldon JE, Kreitman RJ and Pastan I: Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci USA 108: 5742-5747, 2011.
10. King C, Garza EN, Mazor R, Linehan JL, Pastan I, Pepper M and Baker D: Removing T-cell epitopes with computational protein design. Proc Natl Acad Sci USA 111: 8577-8582, 2014.
11. Carlsson J, Nordgren H, Sjöström J, Wester K, Villman K, Bengtsson NO, Ostenstad B, Lundqvist H and Blomqvist C: HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 90: 2344-2348, 2004.
12. Ménard S, Casalini P, Campiglio M, Pupa S, Agresti R and Tagliabue E: HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. Ann Oncol 12 (Suppl 1): S15-S19, 2001.
13. Ahmed S, Sami A and Xiang J: HER2-directed therapy: Current treatment options for HER2-positive breast cancer. Breast Cancer 22: 101-116, 2015.
14. Amiri-Kordestani L, Blumenthal GM, Xu QC, Zhang L, Tang SW, Ha L, Weinberg WC, Chi B, Candau-Chacon R, Hughes P, et al: FDA approval: Ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res 20: 4436-4441, 2014.
15. Löfblom J, Feldwisch J, Tolmachev V, Carlsson J, Ståhl S and Frejd FY: Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 584: 2670-2680, 2010.
16. Li J, Lundberg E, Vernet E, Larsson B, Höidén-Guthenberg I and Gräslund T: Selection of affibody molecules to the ligand-binding site of the insulin-like growth factor-1 receptor. Biotechnol Appl Biochem 55: 99-109, 2010.
17. Friedman M, Nordberg E, Höidén-Guthenberg I, Brismar H, Adams GP, Nilsson FY, Carlsson J and Ståhl S: Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Eng Des Sel 20: 189-199, 2007.
18. Orlova A, Magnusson M, Eriksson TLJ, Nilsson M, Larsson B, Höidén-Guthenberg I, Widström C, Carlsson J, Tolmachev V, Ståhl S, et al: Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 66: 4339-4348, 2006.
19. Kronqvist N, Malm M, Göstring L, Gunneriusson E, Nilsson M, Höidén Guthenberg I, Gedda L, Frejd FY, Ståhl S and Löfblom J: Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules. Protein Eng Des Sel 24: 385-396, 2011.
20. Feldwisch J, Tolmachev V, Lendel C, Herne N, Sjöberg A, Larsson B, Rosik D, Lindqvist E, Fant G, Höidén-Guthenberg I, et al: Design of an optimized scaffold for affibody molecules. J Mol Biol 398: 232-247, 2010.
21. Sörensen J, Sandberg D, Sandström M, Wennborg A, Feldwisch J, Tolmachev V, Aström G, Lubberink M, Garske-Román U, Carlsson J, et al: First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. J Nucl Med 55: 730-735, 2014.
22. Makrides SC, Nygren PA, Andrews B, Ford PJ, Evans KS, Hayman EG, Adari H, Uhlén M and Toth CA: Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor. J Pharmacol Exp Ther 277: 534-542, 1996.
23. Jonsson A, Dogan J, Herne N, Abrahmsén L and Nygren P-A: Engineering of a femtomolar affinity binding protein to human serum albumin. Protein Eng Des Sel 21: 515-527, 2008.
24. Orlova A, Jonsson A, Rosik D, Lundqvist H, Lindborg M, Abrahmsen L, Ekblad C, Frejd FY and Tolmachev V: Sitespecific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody moleculealbumin-binding domain fusion protein. J Nucl Med 54: 961-968, 2013.
25. Tolmachev V, Orlova A, Pehrson R, Galli J, Baastrup B, Andersson K, Sandström M, Rosik D, Carlsson J, Lundqvist H, et al: Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res 67: 2773-2782, 2007.
26. Hopp J, Hornig N, Zettlitz KA, Schwarz A, Fuss N, Müller D and Kontermann RE: The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. Protein Eng Des Sel 23: 827-834, 2010.
27. Andersen JT, Pehrson R, Tolmachev V, Daba MB, Abrahmsén L and Ekblad C: Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J Biol Chem 286: 5234-5241, 2011.
28. Gunneriusson E, Nord K, Uhlén M and Nygren P: Affinity maturation of a Taq DNA polymerase specific affibody by helix shuffling. Protein Eng 12: 873-878, 1999.
29. Sandersjöö L, Jonsson A and Löfblom J: A new prodrug form of Affibody molecules (pro-Affibody) is selectively activated by cancer-associated proteases. Cell Mol Life Sci 72: 1405-1415, 2015.
30. Tolmachev V, Hofström C, Malmberg J, Ahlgren S, Hosseinimehr SJ, Sandström M, Abrahmsén L, Orlova A and Gräslund T: HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [99mTc(CO)3]+, and shows improved biodistribution with reduced hepatic radioactivity accumulation. Bioconjug Chem 21: 2013-2022, 2010.
31. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC and Pastan I: Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 13: 5144-5149, 2007.
32. Kuan CT, Pai LH and Pastan I: Immunotoxins containing Pseudomonas exotoxin that target LeY damage human endothelial cells in an antibody-specific mode: Relevance to vascular leak syndrome. Clin Cancer Res 1: 1589-1594, 1995.